CAP-100 

CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL^[1].

CCR7/CD197

CAP-100 (0.1-10 ng/μL) 表现出与 CCR7 免疫原 SYM1899 (100 ng) 最强的结合，EC₅₀ 为 1.78 ng/mL^[1]。
CAP-100 (0.01-100 μg/mL) 对配体诱导的激活表现出剂量依赖性抑制作用，在用 CCL19 刺激的 CCR7⁺ CHO-K1 细胞中达到最大抑制率接近 100%^[1]。
CAP-100 (0.1-100 μg/mL) 在高实验浓度下可与健康供体的 CCR7⁺ 非肿瘤细胞结合^[1]。
CAP-100 (1-100 μg/mL) 可抑制慢性淋巴细胞白血病 (CLL) 细胞中 CCL19/CCL21 刺激后 D-肌动蛋白的增加^[1]。
CAP-100 (0.1-100 μg/mL，4 小时) 表现出强烈的剂量相关性抑制活性，可抑制 CCR7 驱动的 T-PLL 细胞向 1 μg/mL CCL19 或 CCL21 迁移^[1]。
CAP-100 (10-100 μg/mL，24 小时) 不会介导直接特异性诱导的细胞死亡，但会削弱 CCR7 介导的细胞活力，而 CCR7 是 CLL 中保护细胞的功能^[1]。
CAP-100 (10 μg/mL) 激活人类 NK-92-CD16⁺ 细胞，从而诱导对目标 CLL 细胞产生强效的 ADCC^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CAP-100 (10 μg/mL，静脉注射，单次给药) 可减少 NSG 小鼠体内 CCR7 表达细胞向淋巴结的归巢^[1]。
CAP-100 (25-200 μg，静脉注射，单次给药) 无论剂量多少均能延长中位总生存期，并能减轻携带 Granta-519-luc⁺ 小鼠的肿瘤负担并减少淋巴结浸润^[1]。
与 Trastuzumab (200 μg) (HY-P9907) 相比，CAP-100 (10-200 μg，静脉注射，单次给药) 能显著延长携带 JVM-3 的 SCID 小鼠的寿命^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1236  [NCBI]

P32248

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13(1):1917484.  [Content Brief]